DK0384288T3 - Piperidinforbindelser og deres fremstilling og anvendelse - Google Patents

Piperidinforbindelser og deres fremstilling og anvendelse

Info

Publication number
DK0384288T3
DK0384288T3 DK90102913.2T DK90102913T DK0384288T3 DK 0384288 T3 DK0384288 T3 DK 0384288T3 DK 90102913 T DK90102913 T DK 90102913T DK 0384288 T3 DK0384288 T3 DK 0384288T3
Authority
DK
Denmark
Prior art keywords
preparation
piperidine compounds
piperidine
compounds
Prior art date
Application number
DK90102913.2T
Other languages
English (en)
Inventor
Per Sauerberg
Preben H Olesen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK82589A external-priority patent/DK82589A/da
Priority claimed from DK231589A external-priority patent/DK231589D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of DK0384288T3 publication Critical patent/DK0384288T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK90102913.2T 1989-02-22 1990-02-14 Piperidinforbindelser og deres fremstilling og anvendelse DK0384288T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK82589A DK82589A (da) 1989-02-22 1989-02-22 Piperidinforbindelser, deres fremstilling og anvendelse
DK231589A DK231589D0 (da) 1989-05-12 1989-05-12 Piperidinforbindelser og deres fremstilling og anvendelse

Publications (1)

Publication Number Publication Date
DK0384288T3 true DK0384288T3 (da) 1995-10-02

Family

ID=26064725

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90102913.2T DK0384288T3 (da) 1989-02-22 1990-02-14 Piperidinforbindelser og deres fremstilling og anvendelse

Country Status (22)

Country Link
US (5) US5043345A (da)
EP (2) EP0384288B1 (da)
JP (2) JPH02255680A (da)
KR (1) KR0163763B1 (da)
CN (1) CN1028105C (da)
AR (1) AR247565A1 (da)
AT (1) ATE123030T1 (da)
AU (2) AU629302B2 (da)
CA (2) CA2010578C (da)
DE (1) DE69019550T2 (da)
DK (1) DK0384288T3 (da)
ES (1) ES2072323T3 (da)
FI (2) FI95704C (da)
GR (1) GR3017062T3 (da)
HU (2) HU221623B1 (da)
IE (1) IE69672B1 (da)
IL (2) IL93352A (da)
NO (2) NO900831L (da)
NZ (1) NZ232615A (da)
PH (1) PH26465A (da)
PT (2) PT93241B (da)
RU (1) RU2042676C1 (da)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0372125A1 (en) * 1988-11-08 1990-06-13 Akzo N.V. Oxazole and thiazole derivatives
US5260311A (en) * 1989-02-22 1993-11-09 Novo Nordisk A/S Piperidine compounds and their use
US5328925A (en) * 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5264444A (en) * 1989-02-22 1993-11-23 Novo Nordisk A/S Piperidine compounds and use
EP0459568A3 (en) * 1990-05-31 1992-09-30 Merck Sharp & Dohme Ltd. Substituted oxadiazoles and thiadiazoles for use in the treatment of glaucoma and novel compounds having such use
DK198490D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
DK198590D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
DK198390D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
USRE35822E (en) * 1990-08-21 1998-06-09 Novo Nordisk A/S Heterocyclic compounds
US5418240A (en) * 1990-08-21 1995-05-23 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
US5376668A (en) * 1990-08-21 1994-12-27 Novo Nordisk A/S Heterocyclic compounds
US5527813A (en) * 1990-08-21 1996-06-18 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
WO1992009280A1 (en) * 1990-11-29 1992-06-11 Allergan, Inc. Use of pyridine derivatives in the treatment of ocular hypertension
EP0492903A1 (en) * 1990-12-21 1992-07-01 MERCK SHARP & DOHME LTD. Substituted pyrazines, pyrimidines and pyridazines for use in the treatment of glaucoma
IE922270A1 (en) * 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US5641791A (en) * 1991-08-13 1997-06-24 Novo Nordisk A.S Heterocyclic compounds and their preparation and use
US5175166A (en) * 1991-08-27 1992-12-29 The University Of Toledo Muscarinic agonists
WO1993014089A1 (en) * 1992-01-13 1993-07-22 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
US5244906A (en) * 1992-01-23 1993-09-14 Dowelanco Insect control with substituted oxadiazole and thiadiazole compounds
ES2133416T3 (es) * 1992-10-23 1999-09-16 Merck Sharp & Dohme Ligandos de subtipos de receptores de dopamina.
CZ290550B6 (cs) * 1993-06-04 2002-08-14 Novo Nordisk A/S Krystalický (+) L-hydrogenvinan 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridinu, způsob jeho přípravy, farmaceutický prostředek jej obsahující a jeho pouľití
US5753683A (en) * 1993-08-19 1998-05-19 Novo Nordisk A/S Antipsychotic method
EP0734259B1 (en) * 1993-08-19 2002-06-12 Novo Nordisk A/S Use of piperidine compounds in the treatment of schizophrenia
IL112024A (en) * 1993-12-21 1999-07-14 Novo Nordisk As Pharmaceutical compositions comprising tetrahydropyridine derivatives substituted with oxadiazole or thiadiazole for treating gastrointestinal motility disorders
US5545638A (en) * 1993-12-21 1996-08-13 Novo Nordisk A/S Method of treating gastrointestinal motility disorders
US5605908A (en) * 1994-10-24 1997-02-25 Eli Lilly And Company Heterocyclic compounds and their use
US5672709A (en) * 1994-10-24 1997-09-30 Eli Lilly And Company Heterocyclic compounds and their preparation and use
US5998404A (en) * 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5484794A (en) * 1994-11-09 1996-01-16 Eli Lilly And Company Method for treating anxiety
US5726193A (en) * 1994-10-31 1998-03-10 Eli Lilly And Company Method for treating anxiety
DK0709094T3 (da) * 1994-10-31 2000-07-10 Lilly Co Eli Tetrahydropyridinoxadiazol- eller thiadiazolforbindelse til behandling af angst
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
US5612351A (en) * 1994-11-08 1997-03-18 Novo Nordisk A/S Method of treating urinary bladder dysfunctions
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
TW304167B (da) * 1995-01-30 1997-05-01 Lilly Co Eli
US5605701A (en) * 1995-02-17 1997-02-25 Eli Lilly And Company Transdermal formulation
US5763457A (en) * 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5852037A (en) 1995-11-13 1998-12-22 Eli Lilly And Company Method for treating anxiety
US5998434A (en) * 1995-12-06 1999-12-07 Eli Lilly And Company Composition for treating pain
EA199800535A1 (ru) * 1995-12-07 1998-12-24 Эли Лилли Энд Компани Способ лечения боли
GB9603755D0 (en) * 1996-02-22 1996-04-24 Pfizer Ltd Therapeutic agents
AU2738397A (en) * 1996-04-23 1997-11-12 Eli Lilly And Company Heterocyclic compounds
JP2000509042A (ja) * 1996-04-23 2000-07-18 イーライ・リリー・アンド・カンパニー ヘテロサイクリック化合物群
WO1997040045A1 (en) * 1996-04-24 1997-10-30 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
US6090829A (en) * 1996-08-01 2000-07-18 Eli Lilly And Company Method for treating excessive aggression
EP0821958A3 (en) * 1996-08-01 1998-07-08 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating excessive aggression
EP0821954A1 (en) * 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating mental retardation
US6043258A (en) * 1996-08-01 2000-03-28 Eli Lilly And Company Method for treating disruptive behavior disorders with xanomeline
EP0821956A1 (en) * 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating disruptive behavior disorders
PT821955E (pt) * 1996-08-01 2002-07-31 Lilly Co Eli Uso de 3-(4-hexiloxi-1,2,5-tiadiazol-3-il)-1,2,5,6-tetrahidro-1-metilpiridina (xanomelina) para o tratamento da doenca bipolar
EP0821959A3 (en) * 1996-08-01 1998-09-16 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine for treating nicotine withdrawal
EP0821957A3 (en) * 1996-08-01 1998-04-22 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse
US6117890A (en) * 1996-08-01 2000-09-12 Eli Lilly And Company Method for treating bipolar disorder
EP0934040A1 (en) * 1996-10-23 1999-08-11 Eli Lilly And Company Method for treating dementia due to aids
EP1014974B1 (en) 1997-05-29 2004-08-11 H. Lundbeck A/S Treatment of schizophrenia and psychosis
US6034108A (en) * 1997-07-28 2000-03-07 Eli Lilly And Company Method for treating mental retardation
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6096767A (en) 1999-01-22 2000-08-01 The University Of Toledo Muscarinic receptor agonists
US6376675B2 (en) * 1999-01-22 2002-04-23 The University Of Toledo Muscarinic receptor agonists
US6211204B1 (en) 1999-01-22 2001-04-03 University Of Toledo Muscarinic receptor agonists
US20040023951A1 (en) * 2001-06-18 2004-02-05 Bymaster Franklin Porter Combination therapy for treatment of psychoses
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
CN1821243B (zh) * 2005-08-30 2010-12-08 北京大学 取代的吡啶类m1受体激动剂、其制备方法及其用途
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
JP2009521531A (ja) * 2005-12-27 2009-06-04 ザ・ユニバーシティ・オブ・トレド ムスカリンアゴニスト及びその使用方法
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2296471A4 (en) 2008-05-15 2012-03-14 Univ Toledo MUSCARIC ACID AGONISTS AS COGNITIVE ENHANCERS
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CA2804215C (en) 2009-07-22 2019-10-01 Eric Elenko Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
CA2818025A1 (en) 2010-11-15 2012-05-24 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
WO2012149524A1 (en) 2011-04-29 2012-11-01 The University Of Toledo Muscarinic agonists as enhancers of working memory and cognitive flexibility
EP3083569B1 (en) 2013-12-20 2022-01-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2016205739A1 (en) 2015-06-19 2016-12-22 Belew Mekonnen Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP3347011A4 (en) 2015-09-11 2019-06-19 Chase Pharmaceuticals Corporation MUSCARIN COMBINATION AND ITS USE FOR COMBATING HYPOCHOLINERGEN DISORDERS OF THE CENTRAL NERVOUS SYSTEM
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
CN112601749B (zh) 2018-06-19 2024-03-26 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
AU2019346626B2 (en) 2018-09-28 2022-06-02 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
WO2021097427A1 (en) 2019-11-15 2021-05-20 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders
CN115974863A (zh) * 2021-10-14 2023-04-18 南京迈诺威医药科技有限公司 占诺美林衍生物的苹果酸盐、a晶型及其制备方法和用途
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219646A (en) * 1986-03-27 1990-10-26 Merck Sharp & Dohme Oxadiazole derivatives of azacyclics for treating cns disorders
IL83275A (en) * 1986-09-08 1994-02-27 Novo Nordisk As Compounds 1,2, 4-Oxadiazolyl Pipridine Transformed, their preparation and pharmaceutical preparations containing them
US5017618A (en) * 1987-03-16 1991-05-21 University Of Florida Labile derivatives of ketone analogs of 3-substituted-1-alkylamino-2-propanols and their use as beta-adrenergic blockers
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
NZ225999A (en) * 1987-09-10 1992-04-28 Merck Sharp & Dohme Azacyclic- or azabicyclic-substituted thiadiazole derivatives and pharmaceutical compositions
IE63906B1 (en) * 1987-11-13 1995-06-14 Novo Nordisk As Azabicyclic compounds and their preparation and use
NZ227841A (en) * 1988-02-12 1991-08-27 Merck Sharp & Dohme Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions
DK162892C (da) * 1988-07-04 1992-05-11 Novo Nordisk As 1,2,5,6-tetrahydropyridinforbindelser, deres fremstilling og farmaceutiske praeparater indeholdende disse
US5264444A (en) * 1989-02-22 1993-11-23 Novo Nordisk A/S Piperidine compounds and use
US5260311A (en) * 1989-02-22 1993-11-09 Novo Nordisk A/S Piperidine compounds and their use
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5328925A (en) * 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
DK198490D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
DK198390D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
US5175166A (en) * 1991-08-27 1992-12-29 The University Of Toledo Muscarinic agonists

Also Published As

Publication number Publication date
IL93352A (en) 1994-08-26
KR910015569A (ko) 1991-09-30
PT93241A (pt) 1990-08-31
GR3017062T3 (en) 1995-11-30
EP0384285A2 (en) 1990-08-29
AU4999790A (en) 1990-08-30
CN1045104A (zh) 1990-09-05
NO900831L (no) 1990-08-23
US5559138A (en) 1996-09-24
EP0384288B1 (en) 1995-05-24
FI95704B (fi) 1995-11-30
FI900887A0 (fi) 1990-02-22
KR0163763B1 (ko) 1998-12-01
FI900886A0 (fi) 1990-02-22
US5041455A (en) 1991-08-20
US5284859A (en) 1994-02-08
ES2072323T3 (es) 1995-07-16
AR247565A1 (es) 1995-01-31
EP0384288A3 (en) 1991-04-10
CA2010579A1 (en) 1990-08-22
JPH02255680A (ja) 1990-10-16
PH26465A (en) 1992-07-27
PT93241B (pt) 1996-01-31
DE69019550T2 (de) 1995-10-05
EP0384288A2 (en) 1990-08-29
CA2010578C (en) 2000-05-23
EP0384285A3 (en) 1991-04-24
DE69019550D1 (de) 1995-06-29
IL93352A0 (en) 1990-11-29
HU221623B1 (hu) 2002-12-28
CA2010578A1 (en) 1990-08-22
HU900884D0 (en) 1990-05-28
NO900831D0 (no) 1990-02-21
NZ232615A (en) 1992-06-25
ATE123030T1 (de) 1995-06-15
IE69672B1 (en) 1996-10-02
NO900830D0 (no) 1990-02-21
US5712297A (en) 1998-01-27
JPH02255679A (ja) 1990-10-16
AU4999690A (en) 1990-08-30
NO179639C (no) 1996-11-20
IL93423A0 (en) 1990-11-29
IE900504L (en) 1990-08-22
PT93242A (pt) 1990-08-31
HU211705A9 (en) 1995-12-28
AU629302B2 (en) 1992-10-01
FI95704C (fi) 1996-03-11
NO179639B (no) 1996-08-12
JP2921578B2 (ja) 1999-07-19
US5043345A (en) 1991-08-27
NO900830L (no) 1990-08-23
HUT58326A (en) 1992-02-28
RU2042676C1 (ru) 1995-08-27
CN1028105C (zh) 1995-04-05

Similar Documents

Publication Publication Date Title
DK0384288T3 (da) Piperidinforbindelser og deres fremstilling og anvendelse
DK374389D0 (da) Arylbenzenoxazolidinoner, deres fremstilling og anvendelse
DK0395988T3 (da) Pigmentsammensætninger og deres anvendelse
DK371088A (da) Azacykliske forbindelser, deres fremstilling og anvendelse
DK388989A (da) Acylcyanoguanidiner, deres fremstilling og anvendelse
DK435289D0 (da) Piperazindioner, deres fremstilling og anvendelse
NO903096D0 (no) Termotrope semialifatiske kopolyesteramider og deres fremstilling.
DK293888D0 (da) Fenolderivater og deres fremstilling og anvendelse
DK45188A (da) Substituerede aminderivater og deres anvendelse
DK614088A (da) Fluormethoxyphenyl-dihydropyridiner, deres fremstilling og anvendelse
DK0381135T3 (da) Nye hydroxyperoxider og deres anvendelse
DK225089D0 (da) 2-adamantyl-4-isothiazolin-3-oner, deres fremstilling og anvendelse
DK634089A (da) Polyhydroxybenzyloxypropanolaminer og deres anvendelse
DK592389A (da) Penemderivater, deres fremstilling og anvendelse
DK613988A (da) Fluormethoxyphenyl-dihydropyridiner, deres fremstilling og anvendelse
DK187689D0 (da) Piperidine forbindelser, deres fremstilling og anvendelse
DK523286D0 (da) Piperidine forbindelser, deres fremstilling og anvendelse
DK426986D0 (da) Piperidine forbindelser, deres fremstilling og anvendelse
DK455189A (da) 2,3,4,5-tetrahydro-1-benzoxepiner, deres fremstilling og anvendelse
DK142088D0 (da) 4-phenyl-piperidine forbindelser, deres fremstilling og anvendelse
DK13588D0 (da) Heterocyclylalkyl-2-penem-forbindelser samt deres fremstilling og anvendelse
DK258289D0 (da) Imidazoquinoxalin forbindelser, deres fremstilling og anvendelse
DK142288D0 (da) Quinoxalinforbindelser, deres fremstilling og anvendelse
DK639889D0 (da) Quinoxalinforbindelser, deres fremstilling og anvendelse
DK297188D0 (da) Imidazoquinoxalinforbindelser, deres fremstilling og anvendelse